- 2seventy bio Reports First Quarter Financial Results and Recent Operational Progress
- 2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024
- U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
- 2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron
- 2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors
- FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy
- 2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Progress
- 2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor Conferences
More ▼
Key statistics
On Thursday, 2Seventy Bio Inc (TSVT:NSQ) closed at 4.44, 188.93% above the 52 week low of 1.54 set on Nov 22, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.43 |
---|---|
High | 4.56 |
Low | 4.32 |
Bid | 4.44 |
Offer | 4.55 |
Previous close | 4.48 |
Average volume | 543.35k |
---|---|
Shares outstanding | 51.40m |
Free float | 50.12m |
P/E (TTM) | -- |
Market cap | 230.29m USD |
EPS (TTM) | -4.34 USD |
Data delayed at least 15 minutes, as of May 09 2024 21:00 BST.
More ▼